ALK-positive diffuse large B-cell lymphoma

被引:21
作者
Bubala, H
Maldyk, J
Wlodarska, I
Sonta-Jakimczyk, D
Szczepanski, T
机构
[1] L Warynski Silesian Med Acad, Dept Pediat Hematol & Oncol, PL-41800 Zabrze, Poland
[2] Med Acad, Dept Dev Patomorphol, Warsaw, Poland
[3] Catholic Univ Louvain, Dept Human Genet, B-3000 Louvain, Belgium
[4] Erasmus MC Univ Med Ctr, Dept Immunol, Rotterdam, Netherlands
关键词
anaplastic lymphoma kinase; children; clathrin; diffuse large B-cell lymphoma;
D O I
10.1002/pbc.20396
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Anaplastic lymphoma kinase (ALK) positive diffuse large B-cell lymphoma (DLBCL) is a rare subtype of non-Hodgkins lymphoma. Five Such cases have been described in children. We present a 9-year-old boy, in whom diagnosis of DLBCL has been established in addition to congenital Multiple enchondromatosis. Immunohistopathological evaluation Of tumor biopsy established the final diagnosis of ALK + DLBCL. The clathrin gene (CLTC)-ALK fusion underlying aberrant expression of ALK in the present case was demonstrated by interphase fluorescence ill situ hybridization (FISH) using break-apart rearrangement probes for ALK and CLTC. The disease in this patient was highly resistant to applied chemotherapy regimens and to radiotherapy. Analysis of the disease course in our patient and review of other cases reported previously show that ALK + DLBCL can be all aggressive malignancy that can be cured with conventional chemotherapy protocols only at stage of localized disease.
引用
收藏
页码:649 / 653
页数:5
相关论文
共 15 条
[1]   Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor [J].
Bridge, JA ;
Kanamori, M ;
Ma, ZG ;
Pickering, D ;
Hill, DA ;
Lydiatt, W ;
Lui, MY ;
Colleoni, GWB ;
Antonescu, CR ;
Ladanyi, M ;
Morris, SW .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 159 (02) :411-415
[2]   ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC) [J].
Chikatsu, N ;
Kojima, H ;
Suzukawa, K ;
Shinagawa, A ;
Nagasawa, T ;
Ozawa, H ;
Yamashita, Y ;
Mori, N .
MODERN PATHOLOGY, 2003, 16 (08) :828-832
[3]   Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities [J].
Colomo, L ;
Loong, F ;
Rives, S ;
Pittaluga, S ;
Martínez, A ;
López-Guillermo, A ;
Ojanguren, J ;
Romagosa, V ;
Jaffe, ES ;
Campo, E .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2004, 28 (06) :736-747
[4]   ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma [J].
De Paepe, P ;
Baens, M ;
van Krieken, H ;
Verhasselt, B ;
Stul, M ;
Simons, A ;
Poppe, B ;
Laureys, G ;
Brons, P ;
Vandenberghe, P ;
Speleman, F ;
Praet, M ;
De Wolf-Peeters, C ;
Marynen, P ;
Wlodarska, I .
BLOOD, 2003, 102 (07) :2638-2641
[5]   A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation [J].
Delsol, G ;
Lamant, L ;
Mariame, B ;
Pulford, K ;
Dastugue, N ;
Brousset, P ;
RigalHuguet, F ;
AlSaati, T ;
Cerretti, DP ;
Morris, SW ;
Mason, DY .
BLOOD, 1997, 89 (05) :1483-1490
[6]   ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements:: report of 6 cases [J].
Gascoyne, RD ;
Lamant, L ;
Martin-Subero, JI ;
Lestou, VS ;
Harris, NL ;
Müller-Hermelink, HK ;
Seymour, JF ;
Campbell, LJ ;
Horsman, DE ;
Auvigne, I ;
Espinos, E ;
Siebert, R ;
Delsol, G .
BLOOD, 2003, 102 (07) :2568-2573
[7]  
Jaffe E.S., 2001, PATHOLOGY GENETICS T, V3
[8]   ALK-positive diffuse large B-cell lymphoma of the stomach associated with a clathirin-ALK rearrangement [J].
McManus, DT ;
Catherwood, MA ;
Carey, PD ;
Cuthbert, RJG ;
Alexander, HD .
HUMAN PATHOLOGY, 2004, 35 (10) :1285-1288
[9]   ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript:: report of 2 cases [J].
Onciu, M ;
Behm, FG ;
Downing, JR ;
Shurtleff, SA ;
Raimondi, SC ;
Ma, Z ;
Morris, SW ;
Kennedy, W ;
Jones, SC ;
Sandlund, JT .
BLOOD, 2003, 102 (07) :2642-2644
[10]   The Societe Francaise d'Oncologie Pediatrique LMB89 protocol:: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia [J].
Patte, C ;
Auperin, A ;
Michon, J ;
Behrendt, H ;
Leverger, G ;
Frappaz, D ;
Lutz, P ;
Coze, C ;
Perel, Y ;
Raphaël, M ;
Terrier-Lacombe, MJ .
BLOOD, 2001, 97 (11) :3370-3379